Literature DB >> 28150523

Flexible modeling of the hazard rate and treatment effects in long-term survival studies.

Yolanda Hagar1, James J Dignam2, Vanja Dukic1.   

Abstract

The effects of predictors on time to failure may be difficult to assess in cancer studies with longer follow-up, as the commonly used assumption of proportionality of hazards holding over an extended period is often questionable. Motivated by a long-term prostate cancer clinical trial, we contrast and compare four powerful methods for estimation of the hazard rate. These four methods allow for varying degrees of smoothness as well as covariates with effects that vary over time. We pay particular attention to an extended multiresolution hazard estimator, which is a flexible, semi-parametric, Bayesian method for joint estimation of predictor effects and the hazard rate. We compare the results of the extended multiresolution hazard model to three other commonly used, comparable models: Aalen's additive model, Kooperberg's hazard regression model, and an extended Cox model. Through simulations and the analysis of a large-scale randomized prostate cancer clinical trial, we use the different methods to examine patterns of biochemical failure and to estimate the time-varying effects of androgen deprivation therapy treatment and other covariates.

Entities:  

Keywords:  Biochemical failure; hazard rate; multiresolution hazard; non-proportional hazards; prostate cancer; survival analysis

Mesh:

Substances:

Year:  2017        PMID: 28150523      PMCID: PMC5651995          DOI: 10.1177/0962280216688034

Source DB:  PubMed          Journal:  Stat Methods Med Res        ISSN: 0962-2802            Impact factor:   3.021


  29 in total

1.  Empirical likelihood for cumulative hazard ratio estimation with covariate adjustment.

Authors:  Bin Dong; David E Matthews
Journal:  Biometrics       Date:  2011-11-07       Impact factor: 2.571

2.  Stochastic relaxation, gibbs distributions, and the bayesian restoration of images.

Authors:  S Geman; D Geman
Journal:  IEEE Trans Pattern Anal Mach Intell       Date:  1984-06       Impact factor: 6.226

Review 3.  The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma.

Authors:  Jonathan I Epstein; William C Allsbrook; Mahul B Amin; Lars L Egevad
Journal:  Am J Surg Pathol       Date:  2005-09       Impact factor: 6.394

4.  A linear regression model for the analysis of life times.

Authors:  O O Aalen
Journal:  Stat Med       Date:  1989-08       Impact factor: 2.373

5.  A Multiresolution Hazard Model for Multicenter Survival Studies: Application to Tamoxifen Treatment in Early Stage Breast Cancer.

Authors:  Peter Bouman; Xiao-Li Meng; James Dignam; Vanja Dukić
Journal:  J Am Stat Assoc       Date:  2007-12       Impact factor: 5.033

6.  The analysis of failure times in the presence of competing risks.

Authors:  R L Prentice; J D Kalbfleisch; A V Peterson; N Flournoy; V T Farewell; N E Breslow
Journal:  Biometrics       Date:  1978-12       Impact factor: 2.571

7.  Further results on the non-parametric linear regression model in survival analysis.

Authors:  O O Aalen
Journal:  Stat Med       Date:  1993-09-15       Impact factor: 2.373

8.  The analysis of rates and of survivorship using log-linear models.

Authors:  T R Holford
Journal:  Biometrics       Date:  1980-06       Impact factor: 2.571

9.  Spatially dependent polya tree modeling for survival data.

Authors:  Luping Zhao; Timothy E Hanson
Journal:  Biometrics       Date:  2010-08-19       Impact factor: 2.571

10.  Hazard of recurrence and adjuvant treatment effects over time in lymph node-negative breast cancer.

Authors:  James J Dignam; Vanja Dukic; Stewart J Anderson; Eleftherios P Mamounas; D Lawrence Wickerham; Norman Wolmark
Journal:  Breast Cancer Res Treat       Date:  2008-10-02       Impact factor: 4.872

View more
  1 in total

Review 1.  Measuring and modeling interventions in aging.

Authors:  Nicholas Stroustrup
Journal:  Curr Opin Cell Biol       Date:  2018-08-10       Impact factor: 8.382

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.